A breast cancer drug in South Africa costs $38,000 per year. The average household income? $7,500. That's five times what an entire family makes annually.

In the U.S., Gilead's hepatitis C cure hit the market at $84,000 per treatment course. Production costs? Estimated in the hundreds of dollars.

This isn't a story about greedy corporations or evil pharma executives. It's about incentive structures—and how they shape who gets access to life-saving medications and who doesn't.

In this solo episode, host Noah Volz zooms out from Southern Oregon to examine the global pharmaceutical pricing system that determines what medications are available locally—and what they cost. Even the most innovative community healthcare models hit a ceiling when drug prices consume entire budgets.

You'll discover:

• How p ...